Analyst Rating Update on Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY) has an average broker rating of 1.92, which is interpreted as a Buy, as rated by 13 equity analysts. Nonetheless, 8 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 4 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.

Eli Lilly and Company (LLY) : The highest short term price target forecast on Eli Lilly and Company (LLY) is $116 and the lowest target price is $55. A total of 12 equity analysts are currently covering the company. The average price of all the analysts is $95.42 with a standard deviation of $16.37.

For the current week, the company shares have a recommendation consensus of Buy. Also, Jefferies maintains its view on Eli Lilly and Company (NYSE:LLY) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. Jefferies raises the price target from $100 per share to $105 per share on Eli Lilly and Company. The rating by the firm was issued on July 14, 2016.


Eli Lilly and Company (NYSE:LLY): The stock opened at $83.42 on Wednesday but the bulls could not build on the opening and the stock topped out at $83.42 for the day. The stock traded down to $82.36 during the day, due to lack of any buying support eventually closed down at $82.72 with a loss of -0.72% for the day. The stock had closed at $83.32 on the previous day. The total traded volume was 2,940,868 shares.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Companys products are sold in approximately 120 countries. The Companys human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Companys Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.